<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02091050</url>
  </required_header>
  <id_info>
    <org_study_id>AC-G 01</org_study_id>
    <nct_id>NCT02091050</nct_id>
  </id_info>
  <brief_title>2D vs 3D Planning for High-Dose Rate (HDR) Gynecological Brachytherapy</brief_title>
  <official_title>Clinical and Dosimetric Comparison of 2D Versus 3D HDR Brachytherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AC Camargo Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AC Camargo Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate the limitations of conventional dosimetry (2D) for the adjuvant brachytherapy&#xD;
      treatment and assess whether tridimensional dosimetry relates more faithfully with the&#xD;
      occurrence of adverse effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiotherapy is part of a multidisciplinary strategy to fight cancer in all stages, using&#xD;
      ionizing radiation to cause damage in tumor cells. After radical surgical treatment of&#xD;
      gynecological tumors, pathological findings, such as extension of the myometrium invasion,&#xD;
      histologic grade, and vascular- lymphatic invasion predict the risk of locoregional&#xD;
      recurrence of disease and, consequently, the need for adjuvant treatment. There are two main&#xD;
      methods of adjuvant therapy after hysterectomy for malignant neoplasm of the cervix or&#xD;
      endometrium: external beam radiotherapy with or without booster dose of vaginal vault&#xD;
      brachytherapy or brachytherapy alone. There are few data in the literature and clinical&#xD;
      experience with brachytherapy dimensional (3D) for adjuvant treatment of vaginal vault .&#xD;
&#xD;
      Objective: To demonstrate the limitations of conventional dosimetry (2D) for the adjuvant&#xD;
      brachytherapy treatment and assess whether tridimensional dosimetry relates more faithfully&#xD;
      with the occurrence of adverse effect.&#xD;
&#xD;
      Methods: A prospective study in the Department of Radiation Oncology, Antonio Candido Camargo&#xD;
      Cancer Center will be developed with an expected duration of 14 months and will include 60&#xD;
      patients. Dosimetric parameters of brachytherapy treatment of vaginal vault, able to&#xD;
      influence the incidence of adverse effects will be evaluated. Computed tomography for&#xD;
      planning of external beam radiotherapy and brachytherapy planning will be used, after&#xD;
      placement of intra- vaginal applicator and urinary catheter. For planning brachytherapy two&#xD;
      fast acquisition sequences, one with a urinary catheter not pulled and pulled another with&#xD;
      the probe will be obtained. The prescription dose obey the standard indication of document of&#xD;
      the International Commission on Radiation Units &amp; Measurements (ICRU 38).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dosimetry of Organs of genitourinary and gastrointestinal tracts</measure>
    <time_frame>one week after the tomograph</time_frame>
    <description>Dose in bladder; rectum; small intestine; sigmoid colon; urethra; dose trigone; vaginal cuff.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost analysis with local care.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Genitourinary Toxicity</measure>
    <time_frame>6 weeks</time_frame>
    <description>toxicity associated with the genitourinary tract, using Common Terminology Criteria for Adverse Events v4.0 (CTCAE v4.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Gastrointestinal toxicity</measure>
    <time_frame>6 weeks</time_frame>
    <description>toxicity associated with the gastrointestinal tract, using Common Terminology Criteria for Adverse Events v4.0 (CTCAE v4.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Genitourinary Toxicity</measure>
    <time_frame>3 Years</time_frame>
    <description>toxicity associated with the genitourinary tract, using Common Terminology Criteria for Adverse Events v4.0 (CTCAE v4.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Gastrointestinal toxicity</measure>
    <time_frame>3 Years</time_frame>
    <description>toxicity associated with the gastrointestinal tract, using Common Terminology Criteria for Adverse Events v4.0 (CTCAE v4.0)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cervix Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>HDR Brachytherapy 24Gy (4 x 6Gy)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vaginal vault brachytherapy, associated or not with external beam radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2D HDR planning</intervention_name>
    <description>HDR planning using simple radiograph (2D)</description>
    <arm_group_label>HDR Brachytherapy 24Gy (4 x 6Gy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3D HDR planning</intervention_name>
    <description>HDR planning using computed tomography (3D)</description>
    <arm_group_label>HDR Brachytherapy 24Gy (4 x 6Gy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Malignant neoplasm of the cervix or endometrium;&#xD;
&#xD;
          -  Tomography scan available in the planning system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients did not undergo surgery as initial treatment;&#xD;
&#xD;
          -  Patients without available tomography for planning;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AC Camargo Cancer Center</name>
      <address>
        <city>SÃ£o Paulo</city>
        <state>SP</state>
        <zip>01509 - 010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/27296459</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Sapienza LG, Flosi A, Aiza A, de Assis Pellizzon AC, Chojniak R, Baiocchi G. Volumetric (3D) bladder dose parameters are more reproducible than point (2D) dose parameters in vaginal vault high-dose-rate brachytherapy. Sci Rep. 2016 Jun 14;6:28074. doi: 10.1038/srep28074.</citation>
    <PMID>27296459</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 13, 2014</study_first_submitted>
  <study_first_submitted_qc>March 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2014</study_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AC Camargo Cancer Center</investigator_affiliation>
    <investigator_full_name>Lucas Gomes Sapienza</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>3D Brachytherapy</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>endometrial cancer</keyword>
  <keyword>vaginal vault brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

